Study investigates whether kids with B-ALL need a vaccine booster after immunotherapy

NCT ID NCT07422337

First seen Feb 22, 2026 · Last updated May 02, 2026 · Updated 12 times

Summary

This study looks at children and young adults (up to age 21) who were treated for B-cell acute lymphoblastic leukemia (B-ALL) with a drug called blinatumomab. The goal is to see if their routine childhood vaccines still protect them after this treatment. If the vaccines are no longer effective, the study will test whether giving the vaccines again can restore protection. Researchers will compare these patients to those who did not receive blinatumomab.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-••••

Locations

  • Arkansas Children's

    RECRUITING

    Little Rock, Arkansas, 72202, United States

    Contact Phone: •••-•••-••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Arkansas Children's Northwest

    RECRUITING

    Springdale, Arkansas, 72762, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.